Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
Pipeline
Business cooperation
Product Out-Licensing Co-Development
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2024-12-19
Novamab has been listed on the 2024 Cyzone 100 Future Unicorn List
More
2023-11-13
The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!
More
2023-09-26
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
More
2023-09-18
CDE approves IND application for LQ036 in the treatment of COPD
More
2023-07-04
CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum
More
2023-06-28
LQ036 IND application for COPD accepted by CDE
More
2023-05-25
Novamab presented the latest progress of 3 core assets at the ATS 2023 conference
More
2023-05-12
Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023
More
2023-04-06
Novamab:Systematic Opportunities for Antibody Inhalation Administration
More
2023-01-06
The clinical trial of Novamab's inhaled TSLP nanoantibody drug LQ043H was approved by CDE
More
2022-11-30
LQ036, the world's first inhaled sdAb drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
总计 47 12345